Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

Cedars-Sinai researchers awarded $1.47M grant to study stem cell immune rejection response

Update on Regulus and sanofi-aventis collaboration

Update on Regulus and sanofi-aventis collaboration

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Neurologix announces positive results from Phase 2 trial of NLX-P101 for advanced PD

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

Regulus Therapeutics, sanofi-aventis partner to develop and commercialize microRNA therapeutics

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

USPTO awards Alnylam Notice of Allowance for patent covering methods of inhibiting expression of mutant genes

Many Huntington's disease patients suffer from weight loss, sleeping problems

Many Huntington's disease patients suffer from weight loss, sleeping problems

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

ISB, GIND collaborate on whole-genome sequencing to identify drug targets for Huntington's Disease

Peter and Patricia Gruber Foundation to present 2010 Neuroscience Prize to Robert H. Wurtz

Peter and Patricia Gruber Foundation to present 2010 Neuroscience Prize to Robert H. Wurtz

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

EMA COMP grants orphan medicinal product designation for Raptor's DR Cysteamine for cystinosis

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Alnylam, Mount Sinai scientists discover svRNAs that play a critical role in influenza A virus replication

Neuralstem updates progress of ongoing Phase I human clinical trial for ALS

Neuralstem updates progress of ongoing Phase I human clinical trial for ALS

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Scientists identify new gene candidates that regulate aggregate formations in Huntington's disease

Scientists identify new gene candidates that regulate aggregate formations in Huntington's disease

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

EPO rules in favor of Alnylam Pharmaceuticals’ Kreutzer-Limmer '945 patent

Study confirms inverse association of increase in BMI with lower brain volumes

Study confirms inverse association of increase in BMI with lower brain volumes

Neurologix reports lower net loss of $3.5M for first-quarter 2010

Neurologix reports lower net loss of $3.5M for first-quarter 2010

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.